Objectives The objective of this study was to compare the patterns of smoked and smokeless tobacco use among multimorbid and non-multimorbid middle-aged and older-aged individuals in Karachi, Pakistan.
Study design This was an observational cross-sectional study conducted during 2015–2016.
Study setting and participants A total of 3250 participants aged 30 years and above, residing in the Gulshan-e-Iqbal town, Karachi, Pakistan were enrolled in the study through systematic random sampling. The selected area of residence represents diverse socioeconomic and ethnic groups of the city. People who could speak and write English or Urdu, and those who provided written informed consent were included in the study.
Outcome measures The primary outcome measure of the study was to determine the differences in patterns of tobacco consumption among multimorbid and non-multimorbid adult individuals.
Results We found no difference in patterns of smoked (adjusted OR (aOR) 1.15, 95% CI 0.88 to 1.50, p=0.289) or smokeless tobacco (aOR 1.13, 95% CI 0.86 to 1.48, p= 0.379) use among multimorbid and non-multimorbid individuals. Individuals who perceived tobacco as a risk were less likely to consume smokeless tobacco products.
Conclusion There was no difference in tobacco consumption among individuals with and without multimorbidity. Evidenced-based guidelines are required to implement mental and behavioural interventions in patients with multiple chronic diseases to help them modify their behaviours.
- PRIMARY CARE
- PUBLIC HEALTH
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information. ‘Not applicable’
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
STRENGTHS AND LIMITATIONS OF THIS STUDY
This study had a large sample size using a representative sampling technique.
The study contributes to novel findings about tobacco consumption in the presence of more than two chronic diseases (multimorbidity).
As this study was cross-sectional, the temporal relationship between multimorbidity and tobacco consumption cannot be established.
A participant was said to have multimorbidity on the basis of self-report and not on the basis of diagnosis by a physician.
Every year around 41 million deaths globally are attributed to non-communicable diseases (NCDs) with more than 15 million deaths occurring in the ages between 30 years and 69 years. Major NCDs include cardiovascular diseases (CVDs), cancers, diabetes and chronic respiratory diseases.1 Chronic diseases are contributing to more than half of the burden of the diseases in developing countries and have been the major cause of morbidity and mortality worldwide. Twenty-five per cent of the adult population (>18 years) in Pakistan suffers from at least one chronic disease.2 Annually, tobacco consumption results in around 8 million deaths throughout the world.3 WHO reports that tobacco use accounts for 1 death in every 10 adults4 with around 1 million annual deaths attributable to passive smoking only.3 Tobacco consumption is one of the major behavioural factors leading to multimorbidity.5 Wikstrom et al found smoking a significant predictor of multimorbidity in the Finnish population.6 Eighty per cent of CVDs are attributed to tobacco use while 71% of lung cancer and 42% of chronic respiratory diseases are attributed to smoking only.2 According to Global adult tobacco survey, 19% of adult Pakistani population currently consume tobacco, with 12% using smoked tobacco and 8% using smokeless tobacco).4
Tobacco consumption worsens comorbid chronic conditions including chronic obstructive pulmonary disease, cardiac conditions, hypertension and diabetes.7 Thus, the presence of multimorbidity requires dietary behaviour change. A longitudinal Canadian National Population Health Survey indicated smoking cessation as the most commonly reported behaviour change following the diagnosis of cardiac diseases, diabetes, cancers and stroke.8
Prediagnostic healthy lifestyles were found to be associated with long-term and better survival in patients diagnosed with cancers.9 Smoking cessation lowers the risk of developing pulmonary and cardiac diseases, and results in favourable prognosis in multiple chronic conditions.9 Many tobacco smokers reduce smoking after the diagnosis of chronic diseases including cardiac diseases, diabetes, cancer and stroke, which improves their disease outcomes and quality of life.6 8 10–12 The Framingham Heart Study found that the development of heart diseases and recent hospitalisations were the predictors for smoking cessation.13 Evidence shows the positive effect of smoking cessation on prevention of recurrent CVDs,14 re-infarction rates and deaths regardless of gender, time period, duration of follow-up and the study setting.13 Numerous studies have been conducted on prevalence, patterns and association of tobacco with multimorbidity, however limited research has been conducted in lower-income and middle-income countries including South Asian countries. Also, there is scarce literature examining the behavioural change in the general population, in Pakistan, after developing multimorbidity. Further, there are diverse forms of tobacco consumed in Pakistan as compared with the other parts of the world, which would be worth studying in context of multimorbidity. Therefore, there is a need to investigate the tobacco consumption behaviour and determine its relationship with multimorbidity. The aim of this study is to compare the patterns of tobacco use among multimorbid and non-multimorbid individuals aged 30 years and above, residing in Karachi.
This was an analytical cross-sectional study. This manuscript was written from data collected for the IMPACT (The Burden of Multimorbidity, Its Patterns and Consequences on Health and Well- Being) Study in Karachi, Pakistan, conducted during 2015–2016.
Individuals aged 30 years and above residing in Gulshan-e-Iqbal town, Karachi, were enrolled from February 2015 to April 2015. Populationwise, Karachi is the largest city of Pakistan at a latitude of 24.946218 and longitude of 67.005615.15 Gulshan-e-Iqbal town was one of the populous towns of Karachi with a representation of diverse socioeconomic and ethnic groups.
All participants aged 30 years and above who can read/understand verbal communication in English or Urdu and those who provided written informed consent were enrolled in the study. People with known cognitive impairment and unable to answer the interview questions were excluded from the study.
A sample of 3250 participants was recruited through a systematic random sampling technique. We selected all 13 Union Councils of Gulshan-e-Iqbal town. Proportionate allocation method was used to calculate proportionate estimates of number of individuals from each Union Council. Within each Union Council, houses were selected through systematic random sampling with a random start and then every 109th (kth interval) household was selected (see online supplemental file 1). To achieve the desired sample in each Union Council, a number of camps were set up in different areas of the Union Council. Invitations to participate were sent to all selected households. In addition, invitation banners were also placed at selected areas a few days before the camps were arranged. The response rate for our study was 73%.
The sample size was calculated with OpenEpi software16 through n = [DEFF*Np(1 p)]/ [(d2/Z21-α/2*(N-1)+p*(1 p)]. To the best of our literature search, no local or regional study on multimorbidity was found, hence 50% prevalence was assumed with ±2% confidence limits. A sample size of 2935 was determined as per the confidence level of 97%. A total of 3250 study participants were enrolled in this study.
The data were kept confidential and anonymous.
After obtaining written informed consent, eligible participants were interviewed by trained data collectors with the help of a structured questionnaire. The principal investigator of the IMPACT Study trained the interviewers over two sessions. Further, consensus over the technique of asking each question was drawn in advance in order to reduce interviewer bias.
The questionnaire was designed to collect information on sociodemographic variables including age, gender, marital status, educational status, occupation, family monthly income, information about tobacco, presence of one or more chronic health conditions diagnosed by the healthcare professional and detailed history of medicines taken. Data regarding height, weight, body mass index (BMI), blood pressure and blood glucose level were also collected.
Tobacco use was the outcome variable. Use of smoked tobacco was defined as use of manufactured cigarettes, hand-rolled cigarettes, pipes, cigars, sheesha; however, smokeless tobacco was defined as snuffing by mouth or nose, and chewing tobacco, betel nut or quid. The participants were asked whether they are current users, ex-users or non-users of tobacco; the form of tobacco they used (smokeless or smoked); and frequency (daily/weekly) of tobacco used. Current use of tobacco was asked as: ‘Do you currently smoke tobacco products daily? (Yes/No)’. If the participant responded ‘yes’, he was asked, ‘On an average, how many of the following products do you smoke/chew/snuff each day/week?’. Use of tobacco products in the past was asked as, ‘In the past, did you ever use any smoked tobacco product? (Yes/No)’.
Independent variables included age, gender, socioeconomic status, marital status and risk perception about smoking and substance abuse, and multimorbidity. We assessed socioeconomic status by using Kuppuswamy’s Socioeconomic Status Scale after customising it according to the Pakistani population17 using information from our questionnaire. Socioeconomic status was categorised on the basis of monthly household income. Multimorbidity was defined as the participant’s self-report about being diagnosed with two or more chronic health conditions, along with medication use and laboratory findings for reported disease. Data were recorded for diseases including hypertension, obesity, dyslipidaemia, diabetes, heart diseases (myocardial infarction and chronic ischaemic heart diseases), stroke, migraine, asthma and chronic obstructive pulmonary disease (COPD), anaemia, thyroid disease, diseases of bones and joints, dyspepsia/peptic ulcer, hepatitis B and C, chronic kidney diseases including stones, cancer, disability and mental illness. A person was labelled as obese if they had a BMI ≥30 kg/m2. A person was said to have dyspepsia if they reported four or more symptoms for 6 months, based on the ‘Leeds Dyspepsia Questionnaire’.
Data management and analysis
Variables were precoded and data were entered and analysed in SPSS V.26 (SPSS, Chicago, Illinois, USA). Monthly household income was recorded as a continuous variable in Pakistani rupees and then categorised (<16 000, 16 001–24999, 25 000–39999, 40 000–54999 and≥55 000) for the purpose of analysis. Binary logistic regression was used to calculate crude and adjusted OR to examine the effect of independent variables on outcome variables. Variables such as age, gender, socioeconomic status and marital status were adjusted to account for their potential confounding effects as these variables are reported to be associated with both multimorbidity and tobacco use. A value of p≤0.05 was considered statistically significant.
This manuscript follows the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) reporting guidelines for cross-sectional studies .18
Patient and public involvement
Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.
Data were collected from 3250 individuals; however, due to missing information, we finally constructed our data set with the information from 2843 participants. Out of 3250 participants, some were excluded due to missing data (age=06), (gender=08), (marital status=05), (education=48), (occupation=72), (household monthly income=81), (any form of tobacco use=66). Descriptive analysis revealed that more than half of the individuals (56.6%) had multimorbidity, 18.9% reported currently using any form of tobacco, 9.4% individuals reported using smoked tobacco, while 8.7% were users of smokeless tobacco. Very few individuals reported use of some form of tobacco in the past. Majority of the participants were middle-aged (30–59 years), currently married (84.8%) and belonged to upper-lower class, middle class and upper-middle class socioeconomic status (25.0%, 26.3% and 31.1%, respectively) (table 1).
Bivariate analysis showed that percentages of smoked tobacco users and non-users were almost similar among both multimorbid and apparently healthy individuals (p=0.897). Similarly, proportion of smokeless tobacco users and non-users among multimorbid and non-multimorbid individuals was almost equal (p=0.687) (table 2).
On multivariate analysis, we did not find any difference in behaviour in smoked (p=0.289) or smokeless tobacco (p=0.379) consumption among individuals with multimorbidity and those without multimorbidity after adjusting for effects of age, gender, marital status, socioeconomic status and risk perception. Men, individuals aged 30–39 years, currently married or those separated/divorced/widowed were significantly more likely to consume smoked tobacco (table 3).
Men belonging to the middle or upper socioeconomic status, aged between 30 years and 49 years, and separated/divorced were significantly more likely to consume smokeless tobacco products than others. Individuals perceiving smoked or smokeless tobacco use as a risk to their health were 30% less likely to consume smokeless tobacco. However the association was not significant (table 4).
More than half of the participants were found to be multimorbid. Overall, a considerable percentage of individuals was currently using any form of tobacco. However, we found no difference in the patterns of tobacco consumption (smoked and smokeless tobacco) among multimorbid and non-multimorbid individuals even after adjusting for age, gender, socioeconomic status, marital status and risk perception.
In our study, we found similar patterns of tobacco consumption in those who had multimorbidity and in those who had not. A few studies support the findings that individuals do not reduce their tobacco consumption even after the diagnosis of cancer or CVDs.19 Bassett et al did not find a significant difference between those who were diagnosed with bladder cancer and those who were not. However, 68% of the sample attempted to quit while less than 50% were able to quit successfully.20 A population-based longitudinal study in the UK reported similar behaviour of smokers followed by cancer diagnosis.21 Similarly, a study on 18 456 patients with coronary heart disease (CHD) with 23 physical and 8 mental health conditions in Scotland revealed that individuals with CHD and one or more mental health comorbidities were more likely to be current smokers than those without; it also concluded that there is more need for interventions to target the group with multimorbidity in order to modify their behaviours. We did not find any difference in the patterns of tobacco consumption among multimorbid individuals.22 On the other hand, a study conducted in north-east Melbourne by Gall reported that only 37% of the smokers quit smoking even after 5 years of being diagnosed with stroke.23 The majority of the smokers believed that quitting tobacco smoking would help them reduce its detrimental effects.24 Health problems, either for oneself or for a close relation, were found to be one of the major motivations for smoking cessation.25 Studies have also reported that the individuals who attempted to quit smoking after the diagnosis of CVD gradually restarted after certain period.26 Similar findings were reported by Kim et al, that patients diagnosed with CVD quit smoking right after the diagnosis but restarted gradually after a specific time.27 This may also explain our findings of no difference in both groups; individuals who have multimorbidty may have attempted to quit or may have successfully quit tobacco use soon after the diagnosis but that may have been a temporary change in their behaviour and they may have resumed their tobacco use behaviour after some time.
A study found that smokers who recently quit tobacco, cited their diagnosis of bladder cancer as a reason to quit. They also found that those who never smoked or have quit were more likely to identify tobacco use as a risk factor for lung diseases, lung cancer, head and neck cancers, and heart diseases, than for bladder cancer.20 We were unable to follow up our study participants hence there is lack of evidence whether they have stopped using for the time being and if they had initiated again. In our study, individuals who perceive smoked and smokeless tobacco as harmful, were less likely to consume smokeless tobacco products. This suggests that an individual’s risk perception prevents them from initiating or continuing the smokeless tobacco products however, presence of chronic diseases did not seem to alter their decision. There was no difference in the smoking pattern whether it is perceived as a risk or not. This finding was similar to a study which concluded that those who continue smoking despite being diagnosed with head and neck or lung cancer, do so due to lower risk perception and less willingness to quit.20 This might explain the persistent craving or addiction to nicotine present in smoked tobacco products as supported by the evidence.28 In contrast to these findings, evidence from various studies suggests that a majority of those who were aware of the risks of tobacco use among smokers desired to quit. Further, those who quit smoking perceive smoking as a risk while those who tend to continue their consumption despite being diagnosed with multimorbidity, do not perceive it as a risk.29 30
To the best of our knowledge, this study was the first attempt to contribute to the literature about multimorbidity and patterns of tobacco consumption in multimorbid individuals in the Pakistani population. This study had a large sample size using a probability sampling technique. Previous studies have examined the effect of separate chronic diseases on tobacco consumption, however this study adds to the existing pool of knowledge by reporting the tobacco consumption behaviour of a large number of adults diagnosed with multimorbidity.
This study has a few limitations. First, we collected information at a single point in time and did not follow up, so we could not establish a temporal relationship between multimorbidity and tobacco use. Second, data regarding the extent of smoke and smokeless tobacco was not available so we could not draw the inference if smokers have not quit but decreased it in quantity. Third, diagnosis of chronic illness was subjective and self-reported and was not diagnosed by the physician in the study. The study was done on the residents of Gulshan-e-Iqbal town in Pakistan, thus the findings cannot be generalised.
There is a need to target individuals to modify their behaviour at the time of diagnosis of a chronic disease and they should be routinely counselled about the potential hazards of continuing tobacco use on the progression of their disease and impact on their quality of life. There is a need to integrate counselling to promote behavioural change at the primary care level through clinical psychologists or primary physicians. Evidence shows that physicians have an integral role in facilitating smoking cessation through counselling, being one of the motivating factors.24 In future prospective studies are required to address some of the limitations of this particular study design and analysis.
This study found no difference in the patterns of tobacco use among multimorbid and healthy individuals. Future research studies are needed to explore the change in behaviour among individuals with multimorbidity prospectively. Evidenced-based behavioural interventions need to be implemented at the primary care level and individuals with multimorbidity should be routinely counselled to motivate behaviour change among them.
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information. ‘Not applicable’
Patient consent for publication
This study involves human participants. The study proposal was reviewed and approved by the Institutional Review Board (IRB) of the Dow University of Health Sciences (IRB-554/DUHS/Approval/2015/04). Participants gave informed consent to participate in the study before taking part.
The authors thank the data collectors who helped them in data collection for this study.
Contributors SK coined the idea, conducted the study, analysed the data and drafted the manuscript; SH participated in analysis and interpretation of the study and drafted the manuscript; SZ participated in the analysis of the study and drafting of the manuscript; KS supervised the study, approved the analysis, participated in drafting of the manuscript and approved the manuscript. SK is responsible for the overall content as the guarantor. All authors approved the final version of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.